Biopharmaceutical
Pharmaceutical
Medical

Gilead Sciences

$66.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.49 (2.30%) Today
+$0.02 (0.03%) As of 4:44 PM EDT after-hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!

About GILD

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Employees
11,000
Headquarters
Foster City, California
Founded
1987
Market Cap
82.70B
Price-Earnings Ratio
14.31
Dividend Yield
3.65
Average Volume
5.70M
High Today
$66.44
Low Today
$64.68
Open Price
$65.07
Volume
7.84M
52 Week High
$79.61
52 Week Low
$60.32

Collections

Biopharmaceutical
Pharmaceutical
Medical
Biotechnology
Health
Research And Development
Therapy
Technology

GILD News

BenzingaJul 22

DURECT Soars On Out-Licensing Deal With Gilead For Up To $170M

110
ReutersJul 19

BRIEF-Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

100
Barron'sJul 19

Merck Could Be a Big Winner in the HIV Prevention Market, Analysts Say

709

GILD Earnings

$1.44
$1.60
$1.75
$1.91
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Jul 30, After Hours

Popular Stocks

More GILD News

MarketWatchJul 19

Gilead licensing three pre-clinical programs from Novartis

73
MarketWatchJul 17

Gilead's Chief Scientific Officer to leave next month

81
Washington PostJul 15

Circor and Callon fall while Galapagos, Omnicell rise

0
ReutersJul 15

Gilead invests $5 billion to deepen ties with biotech Galapagos

557
Washington PostJul 15

Gilead Risks Regrets on Pricey Galapagos Partnership

190
Barron'sJul 15

Gilead Sciences Says No to Megamerger, Signs a Deal to Collaborate With Galapagos

34
CNBCJul 15

Gilead deepens Galapagos ties with $5.1 billion deal

32
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.